Dana Hilt Net Worth

Dana Hilt biography

Dr. Dana C. Hilt M.D. serves as Chief Medical Officer of the Company. serves as Chief Medical Officer of the Company. serves as Chief Medical Officer of the Company. From October 2016 to August 2019, Dr. Hilt served as Chief Medical Officer for Lysosomal Therapeutics, Inc., or Lysosomal, a life sciences drug development company in the field of neurodegeneration, where he was responsible for all clinical development activity for a product candidate for the treatment of Parkinson’s Disease. Prior to Lysosomal, beginning in 2006, Dr. Hilt served in the roles of Senior Vice President of Drug Development and Chief Medical Officer for FORUM Pharmaceuticals, Inc., or FORUM, where he oversaw the clinical, chemistry manufacture controls, regulatory and quality control activities for therapies focused on the treatment of cognitive impairment in schizophrenia and Alzheimer’s disease. Prior to FORUM, Dr. Hilt served as the Chief Medical Officer and Senior Vice President of Clinical Research, Medical Affairs, and Development for Ascend Therapeutics US, LLC, or Ascend, a specialty pharmaceutical company concentrating on women’s health and transdermal drug delivery. Before joining Ascend, Dr. Hilt served as the Vice President of Clinical Research at Guilford Pharmaceuticals Inc., or Guilford, a biopharmaceutical company engaged in the research, development, and commercialization of drugs that target the acute care market and neurological indications including Parkinson’s disease and brain cancer. Prior to Guilford, he served as a Director of Clinical Development at Amgen, where he established its clinical neuroscience group. Prior to that, Dr. Hilt served on the staff of the National Institute of Health. He holds an M.D. from Tufts University School of Medicine and a B.S. from the University of Maine.

What's Dana Hilt's mailing address?

Dana's mailing address filed with the SEC is C/O FREQUENCY THERAPEUTICS, INC.,, 75 HAYDEN AVE, SUITE 300, LEXINGTON, MA, 02421.

Insiders trading at Frequency Therapeutics Inc

Over the last 5 years, insiders at Frequency Therapeutics Inc have traded over $11,017,122 worth of Frequency Therapeutics Inc stock and bought 369,233 units worth $5,339,982 . The most active insiders traders include Joel S Marcus, Robert Langer a Marc A Cohen. On average, Frequency Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of $3,858. The most recent stock trade was executed by Richard J. Mitrano on 18 August 2023, trading 464 units of FREQ stock currently worth $269.

What does Frequency Therapeutics Inc do?

frequency therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. through the controlled activation of progenitor cells, frequency enables disease modification without the complexity of genetic engineering. our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the u.s. alone.

Frequency Therapeutics Inc executives and stock owners

Frequency Therapeutics Inc executives and other stock owners filed with the SEC include:

• David Lucchino,
  President, Chief Executive Officer, Co-Founder, Director
• Christopher Loose,
  Co-Founder, Chief Scientific Officer
• Carl LeBel,
  Chief Development Officer
• David L. Lucchino,
  Co-Founder, Pres, CEO & Director
• Wendy S. Arnold,
  Chief People Officer
• Peter P. Pfreundschuh,
  Chief Financial Officer
• Robert Langer,
  Independent Director
• Marc Cohen,
  Lead Independent Chairman of the Board Director
• Joel Marcus,
  Independent Director
• Michael Huang,
  Independent Director
• Timothy Barberich,
  Independent Director
• Carlo Tanzi,
  IR Contact Officer
• Cynthia Feldmann,
  Independent Director
• Dana Hilt,
  Chief Medical Officer
• Ajay Rai,
  Vice President - Business Development
• Richard Mitrano,
  Vice President of Finance and Operations
• Wendy Arnold,
  Chief People Officer
• William Mclean,
  Co-Founder, Vice President - Biology and Regenerative Medicine
• Dr. Carl P. LeBel,
  Chief Devel. Officer
• Dr. Christopher R. Loose,
  Co­-Founder & Chief Scientific Officer
• Dr. William W. Chin M.D.,
  Sr. VP of Translational Medicine
• Dr. Dana C. Hilt,
  Chief Medical Officer
• Dr. Jeff Hrkach,
  Sr. VP of Technology Devel.
• Richard J. Mitrano,
  VP of Fin. & Operations
• William J. McLean Ph.D.,
  Co-founder & Sr. VP of Hearing Biology and Translational Research
• Quentin Mc Cubbin,
  Chief Manufacturing Officer
• James E Deerfield Mgmt L.P....,
  
• Peter P. Pfreundschuh,
  Chief Financial Officer
• Michael Bookman,
  General Counsel and Secretary